Information Provided By: 
Fly News Breaks for April 5, 2018
NVO, LLY
Apr 5, 2018 | 07:43 EDT
SunTrust analyst John Boris keeps his Buy rating and $101 price target on Eli Lilly (LLY), citing the latest developments in Oncology and Diabetes. In Oncology, Boris points to the positive Overall Survival and Progression Free Survival data for Cyramza in second-line hepatocellular carcinoma, though he sees the commercial opportunity in Hepatocellular Carcinoma as limited. In Diabetes, the analyst points to the latest data showing Trulicity gaining market share on Novo Nordisk's (NVO) Victoza in the GLP-1 market.
News For LLY;NVO From the Last 2 Days
NVO
Apr 24, 2024 | 15:59 EDT
Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing "the outrageously high prices" the company charges for the drugs, saying that the drugs "will not do any good for the millions of patients who cannot afford them." Reference Link
